TrialStat EDC

Fast, Compliant, Fully Unified – EDC + IWRS + ePRO + Coding

TrialStat Portal

Real-Time Data & Analytics | Make Study Decision Sooner

Don't Settle For Standard EDC Technology & Services

With TrialStat EDC you'll have your studies up and running quicker, capture your study data more efficiently with fewer errors and reduce your overall study costs.

We're Supporting COVID-19 Research

In times of crisis we all need to step up and help. Effective immediately, we are offering TrialStat’s eClinical Platform and Data Analytics Portal at discounted rates to researchers working on solutions related to COVID-19. With a focus on ease of use, speed of implementation, and real-time data analytics, TrialStat’s data capture suite enables fast study start up and ensures all stakeholders have relevant, customized, timely insight into all aspects of study data and areas of risk or potential delays. We welcome the opportunity to collaborate with our industry colleagues on the path to treatments or cures – please contact covid19@trialstat.com to learn more about this program.

From the entire TrialStat team, we wish you and yours good health as our industry and our communities work together to navigate this outbreak over the coming weeks and months. Thank you for #StayingHome and #FlatteningTheCurve!

Our Latest COVID-19 Research News

Scientists say the best treatment for COVID-19 may be a cocktail of medicines

Excerpt from the article: “More than a dozen drug firms in Massachusetts are urgently searching for a medicine to treat COVID-19, but the most potent therapy may not end up being a single medication. Instead, medical experts say, the most effective way to battle the disease will likely be a combination of drugs taken together.…
Read More

First detailed analysis of immune response to SARS-CoV-2 bodes well for COVID-19 vaccine development

Excerpt from the article: “Newswise — LA JOLLA, CA—Scientists around the world are racing to develop a vaccine to protect against COVID-19 infection, and epidemiologists are trying to predict how the coronavirus pandemic will unfold until such a vaccine is available. Yet, both efforts are surrounded by unresolved uncertainty whether the immune system can mount…
Read More

The Post-COVID-19 Clinical Trial: Finally Understanding the Meaning of Patient Centricity

Excerpt from the article: “Lessons Learned from a Virtual Town Hall held on May 8, 2020 Much of the daily news focus is on the race to produce vaccines and therapies to combat the spread of COVID-19. While this work is undeniably important, we mustn’t lose sight of what keeps our industry running: the patients…
Read More

ProMIS Neurosciences identifies multiple novel targets on SARS CoV-2 for development of a highly accurate COVID-19 antibody test

Excerpt from the article: “TORONTO, Ontario and CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets on the molecular surface of complex proteins, has advanced its program to develop a high-throughput, highly accurate test for detection of antibodies to…
Read More

eCOVID Platform Provides Remote Patient Monitoring

Excerpt from the article: “Engineers at the University of California San Diego have developed a remote monitoring platform for patients who have tested positive for COVID-19 but aren’t in need of hospitalization. The system is being tested by patients in a clinical trial at UC San Diego Health. It is intended to help health care…
Read More

Preventing ‘cytokine storm’ may ease severe COVID-19 symptoms

Excerpt from the article: “For some COVID-19 patients, the body’s immune response may be as destructive as the virus that causes the disease. The persistent high fevers, severe respiratory distress, and lung damage seen in some critically ill patients are all signs of an immune system in overdrive. Now, a new clinical trial will test…
Read More

Study: Remdesivir benefits some COVID-19 patients

Excerpt from the article: “A study published late last week in the New England Journal of Medicine found that hospitalized COVID-19 patients who received Gilead Sciences’ antiviral drug remdesivir recovered a median of 4 days earlier than those who received a placebo. Preliminary findings from the double-blind Adaptive COVID-19 Treatment Trial (ACTT-1), sponsored by the…
Read More

Chest x-rays in the ER predict COVID-19 severity

Excerpt from the Article: “The study findings demonstrate x-ray’s value in helping physicians identify, triage, and treat high-risk patients, wrote a team led by Dr. Danielle Toussie of Mount Sinai Hospital in New York City. “We demonstrate how valuable x-rays can be during this pandemic because, by evaluating disease in different portions of the lungs, we…
Read More

COVID-19 can be seen on CT scans outside the chest

These findings may well change how future screening for COVID-19 infections is conducted. Excerpt from the article: “The study results suggest that radiologists must keep in mind that patients with COVID-19 can initially present with symptoms other than respiratory ones but still have the disease, wrote a team led by Dr. Rydhwana Hossain of the University…
Read More

Finding Our Way Out: How Science Can Overcome the COVID-19 Crisis

Gladstone President Emeritus Sandy Williams explains how Gladstone scientists are leveraging their existing research to address the COVID-19 pandemic. Continue Reading The Article
Read More

COVID-19 Research Event: The Race to Develop Vaccines & Treatments

The world has been greatly impacted by the COVID-19 pandemic and many are waiting in much anticipation for a vaccine and treatments. Many researchers are working tirelessly on COVID-19 research efforts and we have seen many institutions receive funding to support research studies. Join us for an evening of discussion on the important research efforts…
Read More

CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration

Excerpt from the press release: Osaka, JAPAN, and King of Prussia, PA, USA – 7 May 2020 – The CoVIg-19 Plasma Alliance, an unprecedented plasma industry collaboration recently established to accelerate the development of a plasma-derived hyperimmune globulin therapy for COVID-19, is rapidly building momentum. Its membership has expanded globally to include 10 plasma companies, and…
Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?